Skip to main content
. 2021 Oct 6;28(1):71–83. doi: 10.1158/1078-0432.CCR-21-0845

Figure 4.

Figure 4. A, Gene sets enriched in tumor tissue in response to dosing with ivuxolimab from eight paired biopsies of patients dosed with ≥ 1.5 mg/kg indicated that gene sets associated with immune activation and inflammation were among those most enriched (higher positive normalized enrichment score; NES) with the lowest adjusted P values. Biopsies were collected at least 2 weeks from last dose. B, Gene sets associated with immune activation were among the most enriched in a CT26 syngeneic mouse tumor model. Mice were inoculated subcutaneously with 1 × 105 CT26 cells in 0.1 mL of phosphate-buffered saline (PBS). When tumor volume reached 70 to 100 mm3, mice were randomized to the anti-OX40 treatment group or the isotype control antibody group.

A, Gene sets enriched in tumor tissue in response to dosing with ivuxolimab from eight paired biopsies of patients dosed with ≥ 1.5 mg/kg indicated that gene sets associated with immune activation and inflammation were among those most enriched (higher positive normalized enrichment score; NES) with the lowest adjusted P values. Biopsies were collected at least 2 weeks from last dose. B, Gene sets associated with immune activation were among the most enriched in a CT26 syngeneic mouse tumor model. Mice were inoculated subcutaneously with 1 × 105 CT26 cells in 0.1 mL of phosphate-buffered saline (PBS). When tumor volume reached 70 to 100 mm3, mice were randomized to the anti-OX40 treatment group or the isotype control antibody group.